The data from these three datasets, GSE43452, GSE65363 and GSE80729, all showed that treatment with the anticancer agent TMZ clearly upregulated CDKN1A expression in human GBM cells (Figure 4A–4C). This evidence concerns the gene CDKN1A and glioblastoma.